New combo attack on hard-to-treat myeloma enters human testing

This early-phase study tests whether giving a bispecific antibody (CM336) before CAR-T cell therapy can improve outcomes for people with relapsed or refractory multiple myeloma — a blood cancer that has stopped responding to standard treatments. Ten adults will receive the antibody first, then CAR-T cells, and researchers will monitor how well the cancer shrinks and what side effects occur. The goal is to see if this sequential approach is safe and effective enough to warrant larger studies.